Aroa Biosurgery (ASX:ARX) Cash-to-Debt

: 5.18 (As of Sep. 2023)

View and export this data going back to 2020. Start your Free Trial

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Aroa Biosurgery's cash to debt ratio for the quarter that ended in Sep. 2023 was 5.18.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Aroa Biosurgery could pay off its debt using the cash in hand for the quarter that ended in Sep. 2023.

The historical rank and industry rank for Aroa Biosurgery's Cash-to-Debt or its related term are showing as below:

ASX:ARX' s Cash-to-Debt Range Over the Past 10 Years
Min: 2.28 Med: 6.46 Max: 10.93
Current: 5.18

During the past 4 years, Aroa Biosurgery's highest Cash to Debt Ratio was 10.93. The lowest was 2.28. And the median was 6.46.

ASX:ARX's Cash-to-Debt is ranked better than
64.39% of 862 companies
in the Medical Devices & Instruments industry
Industry Median: 2.03 vs ASX:ARX: 5.18

Aroa Biosurgery Cash-to-Debt Historical Data

The historical data trend for Aroa Biosurgery's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Aroa Biosurgery Annual Data

Trend

Mar20

Mar21

Mar22

Mar23

Cash-to-Debt

2.94

2.28

9.77

6.46

Aroa Biosurgery Semi-Annual Data
	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23
Cash-to-Debt	Get a 7-Day Free Trial			10.93	9.77	9.00	6.46	5.18

Competitive Comparison

For the Medical Devices subindustry, Aroa Biosurgery's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Aroa Biosurgery Cash-to-Debt Distribution

For the Medical Devices & Instruments industry and Healthcare sector, Aroa Biosurgery's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Aroa Biosurgery's Cash-to-Debt falls into.

Aroa Biosurgery Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Aroa Biosurgery's Cash to Debt Ratio for the fiscal year that ended in Mar. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	42.997	/	(0.523	+	6.129)
	=	6.46

Aroa Biosurgery's Cash to Debt Ratio for the quarter that ended in Sep. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	32.474	/	(0.775	+	5.498)
	=	5.18

Aroa Biosurgery (ASX:ARX) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Aroa Biosurgery Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Aroa Biosurgery's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Aroa Biosurgery (ASX:ARX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Aroa Biosurgery Ltd (ASX:ARX) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

64 Richard Pearse Drive, Mangere, Airport Oaks, Auckland, NZL, 2022

Website

https://www.aroabio.com

Aroa Biosurgery Ltd is a soft tissue regeneration company which develops, manufactures and sells medical devices for wound and soft tissue repair using its proprietary extracellular matrix (ECM) technology. It is focused on improving the rate and quality of healing in complex wounds and soft tissue reconstruction. The Company is in the business of developing, manufacturing and selling soft tissue repair products. The company's principal market is the United States where it has five key products for sale targeting chronic wounds, hernia, plastics, reconstructive surgery and trauma/limb salvage/tumor surgery.

Aroa Biosurgery (ASX:ARX) Headlines

No Headlines